MDxHealth Grants QIAGEN Rights to MSP Technology
News Jun 21, 2016
MDxHealth SA has announced that it has granted a non-exclusive worldwide license for its patented methylation-specific PCR (MSP) technology to QIAGEN for use in its new CE-marked QIAsure assay to determine cervical cancer risk.
Under the terms of the agreement, QIAGEN has licensed the use of MDxHealth's MSP technology, a proprietary DNA-methylation specific PCR methodology, for the development and commercialization of its new diagnostic test which differentiates patients' risk of developing cervical cancer.
MDxHealth will receive a signing fee plus royalties from future test sales utilizing this technology. QIAGEN reported that the QIAsure test is a highly complementary addition to its leading human papilloma virus (HPV) franchise. Women screening positive for HPV, or with abnormal cells identified by cytology, are at increased risk of developing cervical cancer.
The QIAsure test is the next logical step to assess this risk. More information about the QIAsure product launch can be found at: QIAGEN launches QIAsure Methylation Test to determine cervical cancer risk.
"We are pleased that our Methylation technology can further support QIAGEN's efforts to improve women's health," stated Dr. Jan Groen, CEO of MDxHealth. "Cervical cancer is the fourth most common cancer in women worldwide, with an estimated 528,000 new cases diagnosed and 266,000 deaths each year, so clearly this is an important test."
Penn Medicine Biochemist Receives Major Award for Research on Epigenetic Protein Modifications via Mass SpecNews
Benjamin A.Garcia, PhD, an expert in quantitative proteomics and Presidential Professor of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, has been awarded the Biemann Medal by the American Society for Mass Spectrometry (ASMS). The early-career award recognizes significant achievement in basic or applied mass spectrometry.
Targeting Epigenetic Proteins to Prevent Breast CancerNews
Researchers have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study suggests that inhibiting these proteins with drugs could prevent the development of breast cancer in women at high risk of the disease.READ MORE
Targeting the Engine Room of the Cancer CellNews
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.READ MORE